ELTP — Elite Pharmaceuticals Balance Sheet
0.000.00%
- $450.22m
- $450.97m
- $56.63m
- 69
- 15
- 40
- 36
Annual balance sheet for Elite Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 1.13 | 3.19 | 8.54 | 7.83 | 7.11 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.11 | 3.5 | 3.06 | 3.09 | 19.5 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 10.3 | 12.2 | 18.9 | 21.5 | 40 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7.59 | 6.86 | 6.98 | 10.4 | 14.6 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 25 | 26.2 | 35.1 | 40.9 | 83.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.64 | 5.81 | 6.69 | 7.83 | 13 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 14.3 | 10 | 9.93 | 11.9 | 26.1 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 10.7 | 16.2 | 25.2 | 29 | 57.6 |
Total Liabilities & Shareholders' Equity | 25 | 26.2 | 35.1 | 40.9 | 83.7 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |